Cell-based gene therapy for the prevention and treatment of cardiac dysfunction

Nature Clinical Practice Cardiovascular Medicine

Volumn 4, Issue SUPPL. 1, 2007, Pages

  Penn, Marc S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANGIOPOIETIN; BASIC FIBROBLAST GROWTH FACTOR; CHEMOKINE; CXCL1 CHEMOKINE; GENE PRODUCT; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; LENTIVIRUS VECTOR; MONOCYTE CHEMOTACTIC PROTEIN 3; RETROVIRUS VECTOR; STROMAL CELL DERIVED FACTOR 1; VASCULOTROPIN; VASCULOTROPIN 165;

ACUTE HEART INFARCTION; ARTICLE; CELL BASED GENE THERAPY; CELL HOMING; CELL SURVIVAL; CLINICAL TRIAL; GENE DELIVERY SYSTEM; GENE TRANSFER; GENE VECTOR; GENETIC ENGINEERING; GENETIC IDENTIFICATION; GENETIC SELECTION; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART VENTRICLE REMODELING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MUSCLE REGENERATION; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; TREATMENT OUTCOME;

CELL TRANSPLANTATION; CHEMOKINES; GENE THERAPY; HEART; HEART DISEASES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; PARACRINE COMMUNICATION; REGENERATION; STEM CELL TRANSPLANTATION;

EID: 33846474831     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio0733     Document Type: Article

References (34)

1. Askari A et al. (2004) Cellular, but not direct, adenoviral delivery of VEGF results in improved LV function and neovascularization in dilated ischemic cardiomyopathy. J Am Coll Cardiol 43: 1908-1914
2. Scorsin M et al. (2000) Comparison of the effects of fetal cardiomyocyte and skeletal myoblast transplantation on postinfarction left ventricular function. J Thorac Cardiovasc Surg 119: 1169-1175
3. Menasche P et al. (2003) Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J Am Coll Cardiol 41: 1078-1083
4. Dib N et al. (2005) Safety and feasibility of autologous myoblast transplantation in patients with ischemic cardiomyopathy: Four-year follow-up. Circulation 112: 1748-1755
5. Siminiak T et al. (2004) Autologous skeletal myoblast transplantation for the treatment of postinfarction myocardial injury: Phase I clinical study with 12 months of follow-up. Am Heart J 148: 531-537
6. Orlic D et al. (2001) Bone marrow cells regenerate infarcted myocardium. Nature 410: 701-705
7. Murry CE et al. (2004) Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 428: 664-668
8. Schachinger V et al. (2006) Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 355: 1210-1221
9. Janssens S et al. (2006) Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet 367: 113-121
10. Assmus B et al. (2006) Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med 355: 1222-1232
11. Penn MS (2006) Stem-cell therapy after acute myocardial infarction: The focus should be on those at risk. Lancet 367: 87-88
12. Jiang Y et al. (2002) Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418: 41-49
13. Beltrami AP et al. (2003) Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 114: 763-776
14. Leor J et al. (2006) Human umbilical cord blood-derived CD133+ cells enhance function and repair of the infarcted myocardium. Stem Cells 24: 772-780
15. Pittenger MF and Martin BJ (2004) Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res 95: 9-20
16. Deglurkar I et al.: Mechanical and electrical effects of cell based gene therapy for ischemic cardiomyopathy are independent. Hum Gene Ther, in press
17. Askari A et al. (2003) Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischemic cardiomyopathy. Lancet 362: 697-703
18. Losordo DW et al. (2002) Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 105: 2012-2018
19. Laham RJ et al. (2000) Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: Results of a phase I open-label dose escalation study. J Am Coll Cardiol 36: 2132-2139
20. Stewart DJ et al. (2006) Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: A phase 2 randomized, controlled trial of AdVEGF(121)(AdVEGF121) versus maximum medical treatment. Gene Ther [doi: 10.1038/sj.gt.3302802]
21. Mangi AA et al. (2003) Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med 9: 1195-1201
22. Schenk S et al.: MCP-3 is a myocardial mesenchymal stem cell homing factor. Stem Cells, in press
23. Hofmann M et al. (2005) Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation 111: 2198-2202
24. Ellis SG et al.: Granulocyte colony stimulating factor in patients with large acute myocardial infarction: Results of a pilot dose-escalation randomized trial. Am Heart J, in press
25. Ripa RS et al. (2006) Stem cell mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute ST-elevation myocardial infarction: Result of the double-blind, randomized, placebo-controlled stem cells in myocardial infarction (STEMMI) trial. Circulation 113: 1983-1992
26. Zohlnhofer D et al. (2006) Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. JAMA 295: 1003-1010
27. Honold J et al. (2006) Effects of granulocyte colony simulating factor on functional activities of endothelial progenitor cells in patients with chronic ischemic heart disease. Arterioscler Thromb Vasc Biol 26: 2238-2243
28. Bian J et al. (2006) Engineered cell therapy for sustained local myocardial delivery of nonsecreted proteins. Cell Transplant 15: 67-74
29. Mills WR et al.: Stem cell therapy enhances electrical viability in myocardial infarction. J Mol Cell Cardiol, in press
30. Mills WR et al. (2006) Optical mapping of late myocardial infarction in rats. Am J Physiol Heart Circ Physiol 290: H1298-H1306
31. Kocher AA et al. (2006) Myocardial homing and neovascularization by human bone marrow angioblasts is regulated by IL-8/Gro CXC chemokines. J Mol Cell Cardiol 40: 455-464
32. Askari AT and Penn MS (2002) Targeted gene therapy for the treatment of cardiac dysfunction. Semin Thorac Cardiovasc Surg 14: 167-177
33. Dulak J et al. (2006) New strategies for cardiovascular gene therapy: regulatable pre-emptive expression of pro-angiogenic and antioxidant genes. Cell Biochem Biophys 44: 31-42
34. Lee M et al. (2005) Ischemic injury-specific gene expression in the rat spinal cord injury model using hypoxia-inducible system. Spine 30: 2729-2734